Does Ceruloplasmin affect your response to a COVID-19 vaccine?
Ceruloplasmin showed no clear link to a positive COVID-19 antibody test in a study of 79 people with rheumatoid arthritis and 47 healthy people.
Researchers measured Ceruloplasmin, a protein that carries copper, alongside other blood markers. Rheumatoid arthritis is a long-term disease where the immune system attacks the joints. People with this condition were receiving medicines that reduce immune activity.
The study looked at antibody responses 12–16 weeks after a second COVID-19 vaccine dose. These vaccines used mRNA, instructions that help the body learn to recognize the virus. They are one type of Preventive Vaccines. Antibodies are proteins the immune system makes to recognize a threat.
Blood levels of Zinc, Copper (Serum), and Magnesium differed between vaccinated and unvaccinated people. But those differences did not show a clear link to positive antibody tests. The same was true for the arthritis medicines studied. The source did not report exact blood levels or positive-test rates.
No clear link does not mean no possible effect. This study compared people at one point in time. It did not test whether changing nutrient levels would improve vaccine responses. A positive antibody test also does not tell the whole story of protection.
For BioSocial members, this supports viewing Ceruloplasmin as context, not an immune score. Tracking it alongside Copper (Serum), test dates, and treatment history can make community comparisons more useful. The findings do not establish a target level for better vaccine responses.
What have your Ceruloplasmin results looked like over time, and what context helps you compare notes with others?

Comments
No comments yet.